Audentes Therapeutics (BOLD) to be Acquired by Astellas Pharma for $60/share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/27/2022
- Wall St gains as economic data allays growth concerns
- 'Always Bet on Michael': Dell (DELL) Stock Soars After Crushing Estimates, Analysts Say Results are Impressive
- Credit Suisse Says Tesla (TSLA) Stock Offers an Attractive Entry Point, Sees Nearly 60% Upside From Here
- Citi Downgrades US Equities to Neutral on Recession Risk
- Elon Musk Says Recession Could Last 12 to 18 Months, But 'Actually a Good Thing'
- Wells Fargo (WFC) has fired dozens of loan officers accused of misusing appraisal waivers. Some say the bank gave them mixed signals - Business Insider
- Broadcom (AVGO) to Acquire VMware (VMW) for Approximately $61 Billion in Cash and Stock
- Wall Street jumps on retailer outlook hikes, ebbing Fed fears
- 'His Personality Suggests Resolution Depends on Him Alone': Jefferies Discusses Elon Musk, Cuts PT on Tesla (TSLA) on Increased Risk Profile
- Kraft Heinz (KHC) Receives Notice of Partial Stock Distribution by 3G Capital
- Pre-Open Stock Movers 05/27: Dell, Ulta Surge on Earnings Beats; Gap Plunges (more...)
- After-Hours Stock Movers 05/26: Ulta, Dell Jump on Earnings; Gap, American Eagle Sink (more...)
- Pre-Open Stock Movers 05/26: Retailers Dollar Tree, Macy's, and Williams-Sonoma Jump on Results; Nutanix, Snowflake, NVIDIA Fall (more...)
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
- Pre-Open Stock Movers 05/25: Retailers Express, Nordstrom Gain Following Earnings; Verrica Pharma Sinks on FDA CRL (more...)
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics
December 2, 2019 6:01 PM EST- Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company
- Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and manufacturing expansion for the combined entity
- Acquisition price of US$60 per share in cash, representing a total equity value of approximately US$3 billion
- Transaction expected to be consummated in the first calendar quarter of 2020
TOKYO & SAN FRANCISCO--(BUSINESS WIRE)-- Astellas Pharma... More
